Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Melanoma

Melanoma

Part of Cancer

Subtypes of Melanoma

Uveal Melanoma 4 Lentigo Maligna 1

25 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Melanoma

328 trials tracked for Melanoma: 44 in phase 3 or 4 and 17 with published results. The most-cited published study has 941 citations.

328Trials tracked
44Phase 3 & 4
0Recruiting
17With published results
Phase distribution
Phase 4 5 Phase 3 39 Phase 2 192 Phase 1 56 Other / NA 36
  1. Phase 3 A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) Completed · 941 cited
  2. Phase 3 A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma Completed · 647 cited
  3. Phase 3 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed · 493 cited
  4. Phase 3 Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). Completed · 405 cited
  5. Phase 3 A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma Completed · 394 cited
  6. Phase 3 A Study of Vemurafenib in Participants With Metastatic Melanoma Completed · 292 cited
Show 44 more trials
  1. Phase 3 A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma Completed · 215 cited
  2. Phase 3 Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Completed · 184 cited
  3. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma Completed · 157 cited
  4. Phase 3 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Completed · 70 cited
  5. Phase 3 Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma Completed · 31 cited
  6. Phase 3 Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes Completed · 30 cited
  7. Phase 3 Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma Completed · 25 cited
  8. Phase 3 Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma Completed · 25 cited
  9. Phase 3 A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) Completed · 14 cited
  10. Phase 3 Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) Completed · 7 cited
  11. Phase 3 A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma Completed
  12. Phase 4 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Completed
  13. Phase 4 Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma Completed
  14. Phase 4 Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Completed
  15. Phase 4 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed
  16. Phase 4 Post-Operative Drainage Following Lymph Node Dissection Completed
  17. Phase 3 A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies Completed
  18. Phase 3 A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine Completed
  19. Phase 3 An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma Completed
  20. Phase 3 Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study Completed
  21. Phase 3 A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection Completed
  22. Phase 3 Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) Completed
  23. Phase 3 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes Completed
  24. Phase 3 A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma Completed
  25. Phase 3 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Completed
  26. Phase 3 A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) Completed
  27. Phase 3 A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma Completed
  28. Phase 3 Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma Completed
  29. Phase 3 Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma Completed
  30. Phase 3 Evaluation of Pigmented Skin Lesions With MelaFind(R) System Completed
  31. Phase 3 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma Completed
  32. Phase 3 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Completed
  33. Phase 3 An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma Completed
  34. Phase 3 Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) Completed
  35. Phase 3 Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma Completed
  36. Phase 3 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed
  37. Phase 3 A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma Completed
  38. Phase 3 Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma Completed
  39. Phase 2 Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker Completed
  40. Phase 2 Study of Gene Modified Immune Cells in Patients With Advanced Melanoma Completed
  41. Phase 2 Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma Completed
  42. Phase 2 A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers Completed
  43. Phase 2 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer Completed
  44. Phase 2 Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer Completed

Showing the 50 most-cited and recently-updated of 328 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Dermatology Phase II
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …
CT.gov Mar 30, 2026

Research across Cancer

Related studies from across the Cancer family.

Narrative review discusses ginsenosides for skin conditions including psoriasis and dermatitis with noted evidence gaps
Drug Pipeline Sys. Review
Narrative review discusses ginsenosides for skin conditions including psoriasis and dermatitis with noted evidence gaps Review of ginsenosides for skin conditions shows weak evidence and low absorption
This narrative review examines the use of ginsenosides for various skin conditions, including psoriasis, dermatitis, photoaging, chronic non…
A review of ginsenosides for skin issues like psoriasis and melanoma found the evidence is insufficient and absorption is low.
Frontiers Apr 24, 2026
Meta-analysis identifies germline susceptibility loci for rare cancers including MDS and GIST
Genetics & Precision Medicine Cohort
Meta-analysis identifies germline susceptibility loci for rare cancers including MDS and GIST Genes linked to rare cancers found in large study of over 480,000 people
This meta-analysis of observational cohorts from over 480,000 individuals identified novel germline susceptibility loci for rare cancers.
A huge study of over 480,000 people found new genes that raise the risk of several rare cancers, offering clues for families and doctors.
medRxiv Apr 22, 2026
Melanoma cell subpopulations identified; EIF5A linked to poor outcomes in observational cohort
Genetics & Precision Medicine Cohort
Melanoma cell subpopulations identified; EIF5A linked to poor outcomes in observational cohort New Cell Types Found That Help Fight Melanoma
This observational study analyzed 70,760 cells from 11 samples and clinical specimens from seven patients, alongside the TCGA-SKCM cohort.
Some melanoma cells help your immune system fight the cancer, and a new study identifies seven major cell types linked to better outcomes.
Frontiers Apr 11, 2026
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Allergy & Immunology Sys. Review
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Frontiers Apr 9, 2026
Retrospective analysis identifies molecular correlates of benefit with encorafenib-based therapy in BRAF-mutant melanoma
Dermatology RCT
Retrospective analysis identifies molecular correlates of benefit with encorafenib-based therapy in BRAF-mutant melanoma Melanoma study finds tumor genetics and immune markers may predict treatment benefit
A retrospective exploratory analysis of the phase III COLUMBUS trial in 921 patients with BRAF V600E/K-mutant advanced melanoma found that s…
Patients with advanced melanoma who have higher tumor mutational burden or signs of immune system activity gain the most survival benefit fr…
Apr 4, 2026
Hypofractionated Radiotherapy Shows High Disease Control in Melanoma Brain Metastases
Oncology Cohort
Hypofractionated Radiotherapy Shows High Disease Control in Melanoma Brain Metastases Can a gentler radiation schedule help control melanoma that has spread to the brain?
A retrospective single-center study of 26 patients with melanoma brain metastases found hypofractionated radiotherapy achieved 96% disease c…
A gentle radiation schedule controlled bleeding brain tumors in 100% of cases while shrinking most melanoma growths without severe side effe…
Frontiers Apr 2, 2026

Questions about Melanoma

How does lifileucel TIL therapy work for patients with metastatic melanoma?

Lifileucel is a cell therapy that uses your own immune cells to fight metastatic melanoma after other treatments fail. It involves removing tumor cells, growing immune cells in a lab, and infusing them back with supportive drugs.

Full answer →
Is Keytruda approved for treating unresectable or metastatic melanoma?

Yes, Keytruda (pembrolizumab) is FDA-approved for treating unresectable or metastatic melanoma.

Full answer →
How do MicroRNAs affect the biology of my melanoma cells?

MicroRNAs are small RNA molecules that can promote or suppress melanoma growth, invasion, and spread by controlling gene activity and influencing the tumor's immune environment.

Full answer →